Over the past two decades, robotic surgery has radically changed the landscape for minimally invasive procedures, especially in urology. Specifically, uro-oncological surgery has greatly benefited from robotic platforms, with robot-assisted surgery included in international guidelines as a preferred approach because of better perioperative and postoperative outcomes [1], [2]. The da Vinci surgical system (Intuitive Surgical, Sunnyvale, CA, USA) has represented the main player and benchmark in robotic surgery worldwide for more than 20 yr. However, despite their groundbreaking role in surgery and widespread adoption globally, access to robotic platforms is not uniformly distributed because of high costs, which represent the main limitation for many health care systems. New robotic platforms, such as the Hugo RAS (Medtronic, Minneapolis, MN, USA), Versius (CMR, Cambridge, UK), Senhance (Asensus Surgical, Durham, NC, USA), and others, have been approved and introduced into clinical practice and provide an alternative to Intuitive platforms with potential to reduce associated costs [3], [4]. Here we provide an overview of the distribution of robotic platforms for uro-oncological surgery across different countries on the basis of recent evidence published in the literature.